In reply [8]

Journal of Clinical Oncology

Volumn 25, Issue 9, 2007, Pages 1145-1146

  Philip, Philip A ^a   Mahoney, Michelle R ^b   Allmer, Cristine ^b   Thomas, James ^c   Pitot, Henry C ^b   Kim, George ^d   Donehower, Ross C ^e   Fitch, Tom ^f   Picus, Joel ^g   Erlichman, Charles ^b  

^a WAYNE STATE UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d MAYO CLINIC   (United States)

^e Bunting Blaustein Cancer Research Building ^*  (United States)

^f MAYO CLINIC   (United States)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; BILE DUCT CANCER; CARCINOGENESIS; COLORECTAL CANCER; EXON; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

EID: 34247156508     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.6040     Document Type: Letter

References (3)

1. Philip PA, Mahoney MR, Allmer C, et al: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 24:3069-3074, 2006
2. Gwak G-Y, Yoon J-H, Shin CM, et al: Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinoma. J Cancer Res Clin Oncol 131:649-652, 2005
3. Leone F, Cavalloni G, Pignochino Y, et al: Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res 12:1680-1685, 2006